Editorial
Open Access
- 1 May 2005
- journal article
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 94 (5) , 553-555
- https://doi.org/10.1093/bja/aei103
Abstract
Recombinant activated factor VII (rFVIIa) (NovoSeven®, Novo Nordisk, Bagsvaerd, Denmark) was originally developed to treat bleeding in haemophiliacs with antibodies to factor VIII and IX.12 At present, rFVIIa is approved in the European Union for this indication and also for the treatment of bleeding in FVII deficiency and Glanzmann thrombasthenia refractory to platelet transfusions.This publication has 22 references indexed in Scilit:
- ?Off-license? use of recombinant activated factor VIIBlood Reviews, 2004
- Factor VIIa for Correction of Traumatic CoagulopathyPublished by Wolters Kluwer Health ,2004
- Haemostasis.com: clinical experiences in the investigational use of rFVIIa in the management of severe haemorrhageBritish Journal of Haematology, 2004
- Transfusion medicine service policies for recombinant factor VIIa administrationTransfusion, 2004
- Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhageBritish Journal of Anaesthesia, 2004
- Current Concepts of HemostasisAnesthesiology, 2004
- Cerebral Sinus Thrombosis in a Trauma Patient after Recombinant Activated Factor VII InfusionAnesthesiology, 2004
- Recombinant activated factor VII for the treatment of life-threatening haemorrhageBlood Coagulation & Fibrinolysis, 2003
- Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a reviewBlood Reviews, 2003
- Treatment of traumatic bleeding with recombinant factor VIIaThe Lancet, 1999